Trial Profile
A study on the efficacy and biogenic adaptability affected by ipragliflozin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Dec 2019 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan record.
- 25 Oct 2017 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 04 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.